Trials / Not Yet Recruiting
Not Yet RecruitingNCT04172779
Erlotinib for Hepatocellular Carcinoma Chemoprevention
Phase II Clinical Trial of Low-dose Erlotinib for Hepatocellular Carcinoma Chemoprevention
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- University of Texas Southwestern Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This phase II randomized placebo-controlled trial studies low-dose erlotinib treatment to assess its efficacy and safety to prevent development of hepatocellular carcinoma in patients with advanced liver fibrosis or cirrhosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | erlotinib hydrochloride | Oral administration of erlotinib 50mg (two 25mg capsules) |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2026-02-01
- Primary completion
- 2030-12-01
- Completion
- 2030-12-01
- First posted
- 2019-11-21
- Last updated
- 2025-11-20
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04172779. Inclusion in this directory is not an endorsement.